These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Cytotoxic T‑lymphocyte-associated antigen‑4 polymorphisms and susceptibility to cervical cancer: a meta‑analysis.
    Author: Qiu H, Tang W, Yin P, Cheng F, Wang L.
    Journal: Mol Med Rep; 2013 Dec; 8(6):1785-94. PubMed ID: 24126947.
    Abstract:
    Cytotoxic T‑lymphocyte associated antigen‑4 (CTLA‑4) polymorphisms have been examined for associations with cervical cancer in various countries. The results, however, are inconclusive. The present study aimed to explore whether CTLA‑4 +49 A/G, ‑318 C/T and CT60 G/A polymorphisms confer susceptibility to cervical cancer. A meta‑analysis was performed with 7,794 subjects included in 15 case‑control studies that were published up to January 1, 2013. The results from the meta‑analysis indicated that there were no significant associations between the risk of cervical cancer and the three studied polymorphisms [+49 A/G: Odds ratio (OR), 0.94 and 95% confidence interval (CI), 0.82‑1.07 for GG+AG vs. AA; ‑318 C/T: OR, 1.33 and 95% CI, 0.82‑2.16 for TT+TC vs. CC; and CT60: OR, 0.98 and 95% CI, 0.72‑1.33 for AA+AG vs. GG]. Stratified analyses by ethnicity for the +49 A/G and ‑318 C/T polymorphisms suggested that Asian populations had a decreased risk of cervical cancer for the +49 A/G polymorphism (OR, 0.75 and 95% CI, 0.58‑0.97 for GG+AG vs. AA), but an increased risk for the ‑318 C/T polymorphism (OR, 2.02 and 95% CI, 1.36‑3.00 for TC vs. CC). In summary, the current meta‑analysis showed that the +49 A/G and ‑318 C/T polymorphisms in CTLA‑4 constitute risk factors for cervical cancer.
    [Abstract] [Full Text] [Related] [New Search]